Back to Trial

Oracle Runs

Oracle findings and outcome history for Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (NCT06268574).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:53 PM
Resolution Evidence
Outcome
NO
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Sponsor’s May 14, 2025 RIVER-52 update is trial-specific and explicitly negative: no CRs were observed, predefined efficacy criteria were not met, the study did not advance to Part 2, and enrollment was suspended. A second public filing repeats the same framing.

Sources
Sponsorryvu.com5/14/25
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the European Hematology Association Congress 2025 in June

For RIVER-52, 39 patients received RVU120; no CRs were observed. Ryvu states predefined efficacy criteria were not met, the trial did not advance to Part 2, and enrollment was suspended.

View source
Web Searchfinancialreports.eu6/12/25
Report Content

Public filing on poster PF548 says that despite some blast reductions, no durable CRs were observed in RIVER-52 and enrollment was suspended.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NOAccepted95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor’s May 14, 2025 RIVER-52 update is trial-specific and explicitly negative: no CRs were observed, predefined efficacy criteria were not met, the study did not advance to Part 2, and enrollment was suspended. A second public filing repeats the same framing.

Found Apr 1, 2026, 6:53 PMOutcome date May 14, 2025, 12:00 AMReviewed Apr 1, 2026, 7:03 PM
Sponsorryvu.comMay 14, 2025, 12:00 AM
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the European Hematology Association Congress 2025 in June
For RIVER-52, 39 patients received RVU120; no CRs were observed. Ryvu states predefined efficacy criteria were not met, the trial did not advance to Part 2, and enrollment was suspended.
Web Searchfinancialreports.euJun 12, 2025, 12:00 AM
Report Content
Public filing on poster PF548 says that despite some blast reductions, no durable CRs were observed in RIVER-52 and enrollment was suspended.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:03 PM

Will the results be positive?

PendingtoNOcurrentNO
GPT-5.4 (OpenAI)95% confidenceReviewed Apr 1, 2026, 7:03 PM

Sponsor’s May 14, 2025 RIVER-52 update is trial-specific and explicitly negative: no CRs were observed, predefined efficacy criteria were not met, the study did not advance to Part 2, and enrollment was suspended. A second public filing repeats the same framing.